Vaccine against tuberculosis: What's new?

BMC Infectious Diseases

Volumn 14, Issue , 2014, Pages

  Montagnani, Carlotta ^a   Chiappini, Elena ^a,b   Galli, Luisa ^a,b   de Martino, Maurizio ^a,b  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AD35 AERAS 402 VACCINE; ADAG85A VACCINE; ADENOVIRUS VECTOR; BCG VACCINE; H1 IC31 VACCINE; H56 IC31 VACCINE; HYVAC4 AERAS 404 VACCINE; ID93 GLA SE VACCINE; M72 AS01E VACCINE; MTBVAC VACCINE; MVA85A VACCINE; MYCOBACTERIUM VACCAE VACCINE; RUTI VACCINE; UNCLASSIFIED DRUG; VPM1002 VACCINE; IMMUNOLOGICAL ADJUVANT;

ARTICLE; BCG VACCINATION; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG SAFETY; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; LATENT TUBERCULOSIS; LUNG TUBERCULOSIS; MILIARY TUBERCULOSIS; MYCOBACTERIUM VACCAE; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); SYSTEMATIC REVIEW; TUBERCULOSIS; TUBERCULOUS MENINGITIS; WORLD HEALTH ORGANIZATION; IMMUNIZATION; IMMUNOLOGY; REVIEW;

ADJUVANTS, IMMUNOLOGIC; BCG VACCINE; HUMANS; IMMUNIZATION, SECONDARY; TUBERCULOSIS; TUBERCULOSIS VACCINES;

EID: 84906732814     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-14-S1-S2     Document Type: Article

References (94)

1. Raviglione MC, Uplekar MW: WHO's new Stop TB Strategy. Lancet 2006, 367:952-955.
2. World Health Organization: Global tuberculosis report 2012.[http://apps. who.int/iris/bitstream/10665/75938/1/9789241564502_eng.pdf].
3. Ottenhoff TH, Kaufmann SH: Vaccines against tuberculosis: where are we and where do we need to go? PLoS Pathog 2012, 8:e1002607.
4. Beresford B, Sadoff JC: Update on research and development pipeline: tuberculosis vaccines. Clin Infect Dis 2010, 50(Suppl 3):178-183.
5. Liu J, Tran V, Leung AS, Alexander DC, Zhu B: BCG vaccines: their mechanisms of attenuation and impact on safety and protective efficacy. Hum Vaccin 2009, 5:70-78.
6. Behr MA: BCG-different strains, different vaccines? Lancet Infect Dis 2002, 2:86-92.
7. Hesseling AC, Cotton MF, Fordham von Reyn C, Graham SM, Gie RP, Hussey GD: Consensus statement on the revised World Health Organization recommendations for BCG vaccination in HIV-infected infants. Int J Tuberc Lung Dis 2008, 12:1376-1379.
8. Dalmia N, Ramsay AJ: Prime-boost approaches to tuberculosis vaccine development. Expert Rev Vaccines 2012, 11:1221-33.
9. Colditz GA, Berkey CS, Mosteller F, Brewer TF, Wilson ME, Burdick E, Fineberg HV: The efficacy of bacillus Calmette-Guérin vaccination of newborns and infants in the prevention of tuberculosis: meta-analyses of the published literature. Pediatrics 1995, 96:29-35.
10. Trunz BB, Fine P, Dye C: Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a metaanalysis and assessment of cost-effectiveness. Lancet 2006, 367:1173-1180.
11. Colditz GA, Brewer TF, Berkey CS, Wilson ME, Burdick E, Fineberg HV, Mosteller F: Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA 1994, 271:698-702.
12. World Health Organization: Issues relating to the use of BCG in immunization programmes. A discussion document.[http://www.who.int/vaccine_safety/committee/topics/bcg/en/].
13. Fine PE: Variation in protection by BCG: implications of and for heterologous immunity. Lancet 1995, 346:1339-45.
14. Basu Roy R, Sotgiu G, Altet-Gómez N, Tsolia M, Ruga E, Velizarova S, Kampmann B: Identifying predictors of interferon-γ release assay results in pediatric latent tuberculosis: a protective role of bacillus Calmette-Guerin?: a pTB-NET collaborative study. Am J Respir Crit Care Med 2012, 186:378-384.
15. Rodrigues LC, Pereira SM, Cunha SS, Genser B, Ichihara MY, de Brito SC, Hijjar MA, Dourado I, Cruz AA, Sant'Anna C, Bierrenbach AL, Barreto ML: Effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil: the BCG-REVAC cluster-randomised trial. Lancet 2005, 366:1290-1295.
16. Norouzi S, Aghamohammadi A, Mamishi S, Rosenzweig SD, Rezaei N: Bacillus Calmette-Guérin (BCG) complications associated with primary immunodeficiency diseases. J Infect 2012, 64:543-554.
17. Fallo A, Torrado L, Sanchez A, Cerqueiro C, Shadgrosky L, Lopez EL: Delayed complications of Bacillus Calmette-Guerin (BCG) vaccination in HIV infected children [abstract WeOa0104]. The 3rd IAS Conference on HIV Pathogenesis and Treatment: 24-27 July 2005; Rio de Janeiro [http://iset. aids2010.org/Abstracts/A2176496.aspx].
18. Hesseling AC, Marais BJ, Gie RP, Schaaf HS, Fine PE, Godfrey-Faussett P, Beyers N: The risk of disseminated Bacille Calmette-Guerin (BCG) disease in HIV-infected children. Vaccine 2007, 25:14-18.
19. Global Advisory Committee on Vaccine Safety, 29-30 November 2006. Wkly Epidemiol Rec 2007, 82:18-24.
20. Stop TB partnership: Tuberculosis vaccine in clinical development.[http://www.stoptb.org/wg/new_vaccines/documents.asp].
21. McShane H, Pathan AA, Sander CR, Goonetilleke NP, Fletcher HA, Hill AV: Boosting BCG with MVA85A: the first candidate subunit vaccine for tuberculosis in clinical trials. Tuberculosis 2005, 85:47-52.
22. Tameris MD, Hatherill M, Landry BS, Scriba TJ, Snowden MA, Lockhart S, Shea JE, McClain JB, Hussey GD, Hanekom WA, Mahomed H, McShane H, MVA85A 020 Trial Study Team: Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet 2013, 381:1021-1028.
23. Pathan AA, Minassian AM, Sander CR, Rowland R, Porter DW, Poulton ID, Hill AV, Fletcher HA, McShane H: Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults. Vaccine 2012, 30:5616-5624.
24. Scriba TJ, Tameris M, Smit E, van der Merwe L, Hughes EJ, Kadira B, Mauff K, Moyo S, Brittain N, Lawrie A, Mulenga H, de Kock M, Makhethe L, Janse van Rensburg E, Gelderbloem S, Veldsman A, Hatherill M, Geldenhuys H, Hill AV, Hawkridge A, Hussey GD, Hanekom WA, McShane H, Mahomed H: A phase IIa trial of the new tuberculosis vaccine, MVA85A, in HIV-and/or Mycobacterium tuberculosis-infected adults. Am J Respir Crit Care Med 2012, 185:769-778.
25. Minassian AM, Rowland R, Beveridge NE, Poulton ID, Satti I, Harris S, Poyntz H, Hamill M, Griffiths K, Sander CR, Ambrozak DR, Price DA, Hill BJ, Casazza JP, Douek DC, Koup RA, Roederer M, Winston A, Ross J, Sherrard J, Rooney G, Williams N, Lawrie AM, Fletcher HA, Pathan AA, McShane H: A Phase I study evaluating the safety and immunogenicity of MVA85A, a candidate TB vaccine, in HIV-infected adults. BMJ Open 2011, 1:e000223.
26. Scriba TJ, Tameris M, Mansoor N, Smit E, van der Merwe L, Isaacs F, Keyser A, Moyo S, Brittain N, Lawrie A, Gelderbloem S, Veldsman A, Hatherill M, Hawkridge A, Hill AV, Hussey GD, Mahomed H, McShane H, Hanekom WA: Modified vaccinia Ankara-expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4+ T cells. Eur J Immunol 2010, 40:279-290.
27. Meyer J, Harris SA, Satti I, Poulton ID, Poyntz HC, Tanner R, Rowland R, Griffiths KL, Fletcher HA, McShane H: Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal delivery. Vaccine 2013, 31:1026-1033.
28. Griffiths KL, Pathan AA, Minassian AM, Sander CR, Beveridge NE, Hill AV, Fletcher HA, McShane H: Th1/Th17 cell induction and corresponding reduction in ATP consumption following vaccination with the novel Mycobacterium tuberculosis vaccine MVA85A. PLoS One 2011, 6:e23463.
29. Scriba TJ, Tameris M, Mansoor N, Smit E, van der Merwe L, Mauff K, Hughes EJ, Moyo S, Brittain N, Lawrie A, Mulenga H, de Kock M, Gelderbloem S, Veldsman A, Hatherill M, Geldenhuys H, Hill AV, Hussey GD, Mahomed H, Hanekom WA, McShane H: Dose-finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG-vaccinated infants. J Infect Dis 2011, 203:1832-1843.
30. Safety and immunogenicity of MVA85A prime and Bacille Calmette-Guerin boost vaccination. [http://clinicaltrials.gov/ct2/show/NCT01650389? term=NCT01650389&rank=1].
31. Phase I trial evaluating safety and immunogenicity of MVA85A-IMX313 compared to MVA85A in BCG vaccinated adults. [http://clinicaltrials.gov/ct2/show/NCT01879163?term=mva85a&recr=Open&rank=1].
32. Rowland R, Pathan AA, Satti I, Poulton ID, Matsumiya MM, Whittaker M, Minassian AM, O'Hara GA, Hamill M, Scott JT, Harris SA, Poyntz HC, Bateman C, Meyer J, Williams N, Gilbert SC, Lawrie AM, Hill AV, McShane H: Safety and immunogenicity of an FP9-vectored candidate tuberculosis vaccine (FP85A), alone and with candidate vaccine MVA85A in BCGvaccinated healthy adults: a phase I clinical trial. Hum Vaccin Immunother 2013, 9:50-62.
33. Wang J, Thorson L, Stokes RW, Santosuosso M, Huygen K, Zganiacz A, Hitt M, Xing Z: Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis. J Immunol 2004, 173:6357-6365.
34. Santosuosso M, McCormick S, Zhang X, Zganiacz A, Xing Z: Intranasal boosting with an adenovirus-vectored vaccine markedly enhances protection by parenteral Mycobacterium bovis BCG immunization against pulmonary tuberculosis. Infect Immun 2006, 74:4634-4643.
35. Xing Z, McFarland CT, Sallenave JM, Izzo A, Wang J, McMurray DN: Intranasal mucosal boosting with an adenovirus-vectored vaccine markedly enhances the protection of BCG-primed guinea pigs against pulmonary tuberculosis. PLoS One 2009, 4:e5856.
36. Santosuosso M, Zhang X, McCormick S, Wang J, Hitt M, Xing Z: Mechanisms of mucosal and parenteral tuberculosis vaccinations: adenoviral-based mucosal immunization preferentially elicits sustained accumulation of immune protective CD4 and CD8 T cells within the airway lumen. J Immunol 2005, 174:7986-7994.
37. Study of the Safety and Immunogenicity of an Adenovirus-based Tuberculosis Vaccine. [http://clinicaltrials.gov/ct2/results? term=nct00800670&Search=Search].
38. Mu J, Jeyanathan M, Small CL, Zhang X, Roediger E, Feng X, Chong D, Gauldie J, Xing Z: Immunization with a bivalent adenovirus-vectored tuberculosis vaccine provides markedly improved protection over its monovalent counterpart against pulmonary tuberculosis. Mol Ther 2009, 17:1093-1100.
39. Radosevic K, Wieland CW, Rodriguez A, Weverling GJ, Mintardjo R, Gillissen G, Vogels R, Skeiky YA, Hone DM, Sadoff JC, van der Poll T, Havenga M, Goudsmit J: Protective immune responses to a recombinant adenovirus type 35 tuberculosis vaccine in two mouse strains: CD4 and CD8 T-cell epitope mapping and role of gamma interferon. Infect Immun 2007, 75:4105-4115.
40. Hoft DF, Blazevic A, Stanley J, Landry B, Sizemore D, Kpamegan E, Gearhart J, Scott A, Kik S, Pau MG, Goudsmit J, McClain JB, Sadoff J: A recombinant adenovirus expressing immunodominant TB antigens can significantly enhance BCG-induced human immunity. Vaccine 2012, 30:2098-2108.
41. Abel B, Tameris M, Mansoor N, Gelderbloem S, Hughes J, Abrahams D, Makhethe L, Erasmus M, de Kock M, van der Merwe L, Hawkridge A, Veldsman A, Hatherill M, Schirru G, Pau MG, Hendriks J, Weverling GJ, Goudsmit J, Sizemore D, McClain JB, Goetz M, Gearhart J, Mahomed H, Hussey GD, Sadoff JC, Hanekom WA: The novel tuberculosis vaccine, AERAS-402, induces robust and polyfunctional CD4+ and CD8+ T cells in adults. Am J Respir Crit Care Med 2010, 181:1407-1417.
42. Study of AERAS-402 in Healthy Infants. [http://clinicaltrials.gov/ct2/show/NCT01198366?term=aeras+402&rank=4].
43. Safety and Immunogenicity of AERAS-402 in HIV-infected, Bacillus Calmette-Guerin (BCG)-Vaccinated Adults. [http://clinicaltrials.gov/ct2/show/NCT01017536?term=aeras+402&rank=2].
44. Safety Study of Tuberculosis Vaccines AERAS-402 and MVA85A. [http://clinicaltrials.gov/ct2/show/NCT01683773?term=aeras+402&rank=1].
45. van Dissel JT, Soonawala D, Joosten SA, Prins C, Arend SM, Bang P, Tingskov PN, Lingnau K, Nouta J, Hoff ST, Rosenkrands I, Kromann I, Ottenhoff TH, Doherty TM, Andersen P: Ag85B-ESAT-6 adjuvanted with IC31° promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in volunteers with previous BCG vaccination or tuberculosis infection. Vaccine 2011, 29:2100-2109.
46. Ingvarsson PT, Schmidt ST, Christensen D, Larsen NB, Hinrichs WL, Andersen P, Rantanen J, Nielsen HM, Yang M, Foged C: Designing CAFadjuvanted dry powder vaccines: spray drying preserves the adjuvant activity of CAF01. J Control Release 2013, 167:256-264.
47. You Q, Wu Y, Wu Y, Wei W, Wang C, Jiang D, Yu X, Zhang X, Wang Y, Tang Z, Jiang C, Kong W: Immunogenicity and protective efficacy of heterologous prime-boost regimens with mycobacterial vaccines and recombinant adenovirus-and poxvirus-vectored vaccines against murine tuberculosis. Int J Infect Dis 2012, 16:e816-825.
48. Langermans JA, Doherty TM, Vervenne RA, van der Laan T, Lyashchenko K, Greenwald R, Agger EM, Aagaard C, Weiler H, van Soolingen D, Dalemans W, Thomas AW, Andersen P: Protection of macaques against Mycobacterium tuberculosis infection by a subunit vaccine based on a fusion protein of antigen 85B and ESAT-6. Vaccine 2005, 23:2740-2750.
49. Olsen AW, Williams A, Okkels LM, Hatch G, Andersen P: Protective effect of a tuberculosis subunit vaccine based on a fusion of antigen 85B and ESAT-6 in the aerosol guinea pig model. Infect Immun 2004, 72:6148-6150.
50. van Dissel JT, Arend SM, Prins C, Bang P, Tingskov PN, Lingnau K, Nouta J, Klein MR, Rosenkrands I, Ottenhoff TH, Kromann I, Doherty TM, Andersen P: Ag85B-ESAT-6 adjuvanted with IC31 promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in naïve human volunteers. Vaccine 2010, 28:3571-3581.
51. Ottenhoff TH, Doherty TM, van Dissel JT, Bang P, Lingnau K, Kromann I, Andersen P: First in humans: a new molecularly defined vaccine shows excellent safety and strong induction of long-lived Mycobacterium tuberculosis-specific Th1-cell like responses. Hum Vaccin 2010, 6:1007-1015.
52. Skeiky YA, Dietrich J, Lasco TM, Stagliano K, Dheenadhayalan V, Goetz MA, Cantarero L, Basaraba RJ, Bang P, Kromann I, McMclain JB, Sadoff JC, Andersen P: Non-clinical efficacy and safety of HyVac4:IC31 vaccine administered in a BCG prime-boost regimen. Vaccine 2010, 28:1084-1093.
53. Dietrich J, Aagaard C, Leah R, Olsen AW, Stryhn A, Doherty TM, Andersen P: Exchanging ESAT6 with TB10.4 in an Ag85B fusion molecule-based tuberculosis subunit vaccine: efficient protection and ESAT6-based sensitive monitoring of vaccine efficacy. J Immunol 2005, 174:6332-6339.
54. Billeskov R, Elvang TT, Andersen PL, Dietrich J: The HyVac4 subunit vaccine efficiently boosts BCG-primed anti-mycobacterial protective immunity. PLoS One 2012, 7:e39909.
55. AERAS-404/HyVac4. [http://192.240.162.26/candidates].
56. Phase 1/II, Safety and Immunogenicity Study of AERAS-404 in BCGPrimed Infants. [http://clinicaltrials.gov/ct2/results?term=aeras +404&Search=Search].
57. Bertholet S, Ireton GC, Ordway DJ, Windish HP, Pine SO, Kahn M, Phan T, Orme IM, Vedvick TS, Baldwin SL, Coler RN, Reed SG: A defined tuberculosis vaccine candidate boosts BCG and protects against multidrug-resistant Mycobacterium tuberculosis. Sci Transl Med 2010, 2:53-74.
58. Baldwin SL, Bertholet S, Reese VA, Ching LK, Reed SG, Coler RN: The importance of adjuvant formulation in the development of a tuberculosis vaccine. J Immunol 2012, 188:2189-2197.
59. Baldwin SL, Ching LK, Pine SO, Moutaftsi M, Lucas E, Vallur A, Orr MT, Bertholet S, Reed SG, Coler RN: Protection against Tuberculosis with Homologous or Heterologous Protein/Vector Vaccine Approaches Is Not Dependent on CD8+ T Cells. J Immunol 2013, 191:2514-2525.
60. Phase 1 ID93 + GLA-SE Vaccine Trial in Healthy Adult Volunteers. [http://clinicaltrials.gov/ct2/show/NCT01599897?term=id93+gla&rank=1].
61. Phase 1 ID93 + GLA-SE Vaccine Trial in BCG-Vaccinated Healthy Adult Volunteers. [http://clinicaltrials.gov/ct2/show/NCT01927159?term=id93 +gla&rank=2].
62. Lin PL, Dietrich J, Tan E, Abalos RM, Burgos J, Bigbee C, Bigbee M, Milk L, Gideon HP, Rodgers M, Cochran C, Guinn KM, Sherman DR, Klein E, Janssen C, Flynn JL, Andersen P: The multistage vaccine H56 boosts the effects of BCG to protect cynomolgus macaques against active tuberculosis and reactivation of latent Mycobacterium tuberculosis infection. J Clin Invest 2012, 122:303-314.
63. Aagaard C, Hoang T, Dietrich J, Cardona PJ, Izzo A, Dolganov G, Schoolnik GK, Cassidy JP, Billeskov R, Andersen P: A multistage tuberculosis vaccine that confers efficient protection before and after exposure. Nat Med 2011, 17:189-194.
64. A Phase I/IIa Safety & Immunogenicity of AERAS-456 in HIV-Negative Adults With & Without Latent Tuberculosis Infection. [http://clinicaltrials. gov/ct2/show/NCT01865487?term=h56+ic31&rank=1].
65. Von Eschen K, Morrison R, Braun M, Ofori-Anyinam O, De Kock E, Pavithran P, Koutsoukos M, Moris P, Cain D, Dubois MC, Cohen J, Ballou WR: The candidate tuberculosis vaccine Mtb72F/AS02A: Tolerability and immunogenicity in humans. Hum Vaccin 2009, 5:475-482.
66. Leroux-Roels I, Forgus S, De Boever F, Clement F, Demoitié MA, Mettens P, Moris P, Ledent E, Leroux-Roels G, Ofori-Anyinam O, M72 Study Group: Improved CD4+ T cell responses to Mycobacterium tuberculosis in PPDnegative adults by M72/AS01 as compared to the M72/AS02 and Mtb72F/AS02 tuberculosis candidate vaccine formulations: a randomized trial. Vaccine 2013, 31:2196-2206.
67. Reed SG, Coler RN, Dalemans W, Tan EV, DeLa Cruz EC, Basaraba RJ, Orme IM, Skeiky YA, Alderson MR, Cowgill KD, Prieels JP, Abalos RM, Dubois MC, Cohen J, Mettens P, Lobet Y: Defined tuberculosis vaccine, Mtb72F/AS02A, evidence of protection in cynomolgus monkeys. Proc Natl Acad Sci U S A 2009, 106:2301-2306.
68. Tsenova L, Harbacheuski R, Moreira AL, Ellison E, Dalemans W, Alderson MR, Mathema B, Reed SG, Skeiky YA, Kaplan G: Evaluation of the Mtb72F polyprotein vaccine in a rabbit model of tuberculous meningitis. Infect Immun 2006, 74:2392-2401.
69. Brandt L, Skeiky YA, Alderson MR, Lobet Y, Dalemans W, Turner OC, Basaraba RJ, Izzo AA, Lasco TM, Chapman PL, Reed SG, Orme IM: The protective effect of the Mycobacterium bovis BCG vaccine is increased by coadministration with the Mycobacterium tuberculosis 72-kilodalton fusion polyprotein Mtb72F in M.tuberculosis-infected guinea pigs. Infect Immun 2004, 72:6622-6632.
70. Spertini F, Audran R, Lurati F, Ofori-Anyinam O, Zysset F, Vandepapelière P, Moris P, Demoitié MA, Mettens P, Vinals C, Vastiau I, Jongert E, Cohen J, Ballou WR: The candidate tuberculosis vaccine Mtb72F/AS02 in PPD positive adults: a randomized controlled phase I/II study. Tuberculosis 2013, 93:179-188.
71. McNamara LA, He Y, Yang Z: Using epitope predictions to evaluate efficacy and population coverage of the Mtb72f vaccine for tuberculosis. BMC Immunol 2010, 11:18.
72. Day CL, Tameris M, Mansoor N, van Rooyen M, de Kock M, Geldenhuys H, Erasmus M, Makhethe L, Hughes EJ, Gelderbloem S, Bollaerts A, Bourguignon P, Cohen J, Demoitié MA, Mettens P, Moris P, Sadoff JC, Hawkridge A, Hussey GD, Mahomed H, Ofori-Anyinam O, Hanekom WA: Induction and regulation of T-cell immunity by the novel tuberculosis vaccine M72/AS01 in South African adults. Am J Respir Crit Care Med 2013, 188:492-502.
73. Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine in Adults With TB Disease. [http://clinicaltrials.gov/ct2/show/NCT01424501? term=692342&recr=Open&rank=1].
74. Study to Evaluate the Efficacy of GlaxoSmithKline (GSK) Biologicals' Candidate Tuberculosis (TB) Vaccine in Healthy Adults. [http://clinicaltrials. gov/ct2/show/NCT01755598?term=692342&recr=Open&rank=2].
75. Grode L, Ganoza CA, Brohm C, Weiner J 3rd, Eisele B, Kaufmann SH: Safety and immunogenicity of the recombinant BCG vaccine VPM1002 in a phase 1 open-label randomized clinical trial. Vaccine 2013, 31:1340-1348.
76. Desel C, Dorhoi A, Bandermann S, Grode L, Eisele B, Kaufmann SH: Recombinant BCG ?ureC hly+ induces superior protection over parental BCG by stimulating a balanced combination of type 1 and type 17 cytokine responses. J Infect Dis 2011, 204:1573-1584.
77. Farinacci M, Weber S, Kaufmann SH: The recombinant tuberculosis vaccine rBCG δureC::hly(+) induces apoptotic vesicles for improved priming of CD4(+) and CD8(+) T cells. Vaccine 2012, 30:7608-7614.
78. Study to Evaluate Safety and Immunogenicity of VPM1002 in Comparison With BCG in Newborn Infants in South Africa. [http://clinicaltrials.gov/ct2/show/NCT01479972?term=vpm1002&rank=2].
79. Kaufmann SH, Gengenbacher M: Recombinant live vaccine candidates against tuberculosis. Curr Opin Biotechnol 2012, 23:900-907.
80. Hoft DF, Blazevic A, Abate G, Hanekom WA, Kaplan G, Soler JH, Weichold F, Geiter L, Sadoff JC, Horwitz MA: A new recombinant bacille Calmette-Guérin vaccine safely induces significantly enhanced tuberculosis-specific immunity in human volunteers. J Infect Dis 2008, 198:1491-1501.
81. Arbues A, Aguilo JI, Gonzalo-Asensio J, Marinova D, Uranga S, Puentes E, Fernandez C, Parra A, Cardona PJ, Vilaplana C, Ausina V, Williams A, Clark S, Malaga W, Guilhot C, Gicquel B, Martin C: Construction, characterization and preclinical evaluation of MTBVAC, the first live-attenuated M. tuberculosis-based vaccine to enter clinical trials. Vaccine 2013, 31:4867-4873.
82. Nambiar JK, Pinto R, Aguilo JI, Takatsu K, Martin C, Britton WJ, Triccas JA: Protective immunity afforded by attenuated, PhoP-deficient Mycobacterium tuberculosis is associated with sustained generation of CD4+ T-cell memory. Eur J Immunol 2012, 42:385-392.
83. Martin C, Williams A, Hernandez-Pando R, Cardona PJ, Gormley E, Bordat Y, Soto CY, Clark SO, Hatch GJ, Aguilar D, Ausina V, Gicquel B: The live Mycobacterium tuberculosis phoP mutant strain is more attenuated than BCG and confers protective immunity against tuberculosis in mice and guinea pigs. Vaccine 2006, 24:3408-3419.
84. Kaufmann SH, Gengenbacher M: Recombinant live vaccine candidates against tuberculosis. Curr Opin Biotechnol 2012, 23:900-7.
85. Cardona PJ: RUTI: a new chance to shorten the treatment of latent tuberculosis infection. Tuberculosis 2006, 86:273-289.
86. Vilaplana C, Gil O, Cáceres N, Pinto S, Díaz J, Cardona PJ: Prophylactic effect of a therapeutic vaccine against TB based on fragments of Mycobacterium tuberculosis. PLoS One 2011, 6:e20404.
87. Vilaplana C, Ruiz-Manzano J, Gil O, Cuchillo F, Montané E, Singh M, Spallek R, Ausina V, Cardona PJ: The tuberculin skin test increases the responses measured by T cell interferon-gamma release assays. Scand J Immunol 2008, 67:610-617.
88. Vilaplana C, Montané E, Pinto S, Barriocanal AM, Domenech G, Torres F, Cardona PJ, Costa J: Double-blind, randomized, placebo-controlled Phase I Clinical Trial of the therapeutical antituberculous vaccine RUTI. Vaccine 2010, 28:1106-1116.
89. Dlugovitzky D, Fiorenza G, Farroni M, Bogue C, Stanford C, Stanford J: Immunological consequences of three doses of heat-killed Mycobacterium vaccae in the immunotherapy of tuberculosis. Respir Med 2006, 100:1079-1087.
90. Yang XY, Chen QF, Li YP, Wu SM: Mycobacterium vaccae as adjuvant therapy to anti-tuberculosis chemotherapy in never-treated tuberculosis patients: a meta-analysis. PLoS One 2011, 6:e23826.
91. Lahey T, Arbeit RD, Bakari M, Horsburgh CR, Matee M, Waddell R, Mtei L, Vuola JM, Pallangyo K, von Reyn CF: Immunogenicity of a protective whole cell mycobacterial vaccine in HIV-infected adults: a phase III study in Tanzania. Vaccine 2010, 28:7652-7658.
92. von Reyn CF, Mtei L, Arbeit RD, Waddell R, Cole B, Mackenzie T, Matee M, Bakari M, Tvaroha S, Adams LV, Horsburgh CR, Pallangyo K, DarDar Study Group: Prevention of tuberculosis in Bacille Calmette-Guérin-primed, HIV-infected adults boosted with an inactivated whole-cell mycobacterial vaccine. AIDS 2010, 24:675-685.
93. Vuola JM, Ristola MA, Cole B, Järviluoma A, Tvaroha S, Rönkkö T, Rautio O, Arbeit RD, von Reyn CF: Immunogenicity of an inactivated mycobacterial vaccine for the prevention of HIV-associated tuberculosis: a randomized, controlled trial. AIDS 2003, 17:2351-2355.
94. Yang XY, Chen QF, Cui XH, Yu Y, Li YP: Mycobacterium vaccae vaccine to prevent tuberculosis in high risk people: a meta-analysis. J Infect 2010, 60:320-330.